• 

  DCGI approves Covaxin for phase 2/3 trials on children

  News | May 13, 2021 11:20 IST

  The DGCI has approved Bharat Biotech's COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years. The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.

• 

  DGCI approves Bharat Biotech's Covaxin for phase 2/3 trials on children

  India | May 13, 2021 11:45 IST

  Covaxin is currently being administered to the people in the country along with Covishield. Hyderabad-based Bharat Biotech is manufacturing Covaxin.

• 

  Covishield monthly production to touch 10 crore by August, Covaxin 7.8 crore

  India | May 13, 2021 7:55 IST

  Serum Institute and Bharat Biotech have submitted to the Centre that they can ramp up production of Covishield and Covaxin to 10 crore and 7.8 crore doses, respectively, by August.

• 

  Super 100: Covaxin centres in Delhi closed as Bharat Biotech refused to provide doses: Manish Sisodia

  News | May 12, 2021 22:12 IST

  Several Covid-19 vaccination centres in Delhi are closed due to shortage of vaccine. Manish Sisodia has claimed that Covaxin manufacturer Bharat Biotech has declined to provide vaccine.

• 

  Disheartening to hear some states complaining about Covaxin supply: Bharat Biotech

  India | May 12, 2021 21:41 IST

  Bharat Biotech co-founder and Joint MD Suchitra Ella tweeted this on Wednesday amid reports of some states voicing their unhappiness over supplies.

• 

  Bharat Biotech to begin vaccine trial for those between 2-18 years-old | Experts view

  News | May 13, 2021 17:52 IST

  Vaccine maker Bharat Biotech will soon begin the clinical trial for those falling between the age of 2-18 years old.

• 

  Polio vaccine maker BIBCOL to manufacture Covaxin at UP's Bulandshahr plant

  India | May 13, 2021 10:52 IST

  BIBCOL will manufacture 2 crore doses of Covaxin every month at its Bulandshahar plant in Uttar Pradesh.

• 

  Expert panel approves Covaxin for phase 2/3 trials on children

  India | May 12, 2021 11:14 IST

  The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.

• 

  Fact Check: Bharat Biotech's Covaxin approved for children above 12 years?

  India | May 10, 2021 12:37 IST

  Government has said that a tweet claiming that Covaxin has been approved for children above 12 years of age is fake.

• 

  Bharat Biotech commences direct supply of 'Covaxin' to 14 states

  India | May 10, 2021 12:13 IST

  The company is supplying vaccines to Andhra Pradesh, Assam, Chhattisgarh, Gujarat, Jammu & Kashmir, Jharkhand, Madhya Pradesh, Odisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal.

• 

  Covishield production in full swing in Pune, will return to India soon, says Adar Poonawalla

  India | May 02, 2021 9:37 IST

  Serum Institute of India CEO Aadar Poonawalla has said that the production of COVID-19 vaccine Covishield is in full swing in Pune and he will review the operations once he is back in the country.

Advertisement
• 

  Covaxin price reduced from Rs 600 to Rs 400 per dose for states, says Bharat Biotech

  India | April 29, 2021 18:15 IST

  Covaxin vaccine maker Bharat Biotech on Thursday announced a drop in the price of its vaccine that will be made available to the state governments.

• 

  Maharashtra govt writes to SII, Bharat Biotech about their demand of COVID-19 vaccines

  India | April 28, 2021 11:16 IST

  Maharashtra remains one of the worst-COVID-affected states in the country. As many as 66,358 new cases, 895 deaths and 67,752 recoveries were reported on Tuesday. The total case tally stands at 44,100,85.

• 

  Reduce vaccine price: Govt tells Serum Institute, Bharat Biotech

  India | April 26, 2021 20:16 IST

  The move has come days ahead of India's planned drive to inoculate all aged above 18. The vaccination drive is set to begin May 1.

• 

  Bharat Biotech seeks DCGI's nod to extend shelf life of Covaxin

  India | April 25, 2021 17:01 IST

  Bharat Biotech has written to India's drug regulator seeking extension of the shelf-life of its indigenously developed COVID-19 vaccine Covaxin from six to 24 months, sources said on Sunday. 

• 

  Covaxin to cost Rs 600 per dose for state hospitals, Rs 1,200 to private ones

  India | April 24, 2021 23:06 IST

  Covaxin, India's indigeniously developmed coronavirus vaccine, will be sold at Rs 600 per dose for state hospitals and Rs 1,200 per dose for private hospitals, vaccine maker Bharat Biotech has informed.

• 

  COVID: Andhra Pradesh govt places order for 4.08 cr doses each of Covaxin, Covishield

  India | April 24, 2021 18:52 IST

  Govt Principal Secy (Covid Management and Vaccination) wrote letters to Bharat Biotech MD Krishna Yella and Serum Institute of India Limited CEO Adar Poonawalla in this regard.

• 

  'Understand India's pharmaceutical needs': US to consider lifting ban on vaccine raw material supply

  World | April 20, 2021 14:50 IST

  The Biden administration has conveyed to India that they understand India's pharmaceutical requirements and has promised to review embargo on Covid-19 vaccine raw material.

• 

  Govt to provide Rs 4,500 cr booster to SII, Bharat Biotech for ramping up Covid vaccine production

  India | April 20, 2021 12:30 IST

  COVID-19 vaccine: SII will supply 200 million doses and Bharat Biotech is to supply another 90 million doses to the government by July at a pre-agreed rate of Rs 150 per dose.  

• 

  DGCI grants approval for clinical trials for third dose of Covaxin

  India | April 02, 2021 13:03 IST

  The expert panel of India's drug regulator, DCGI, has permitted Bharat Biotech to give the third dose of Covaxin to a few volunteers in its clinical trials of the COVID-19 vaccine.